63618-07-5

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Azabicyclo[3.1.0] hexane-1-carboxylic acid, 3-(phenylMethyl)-, ethyl ester is used as a chiral building block for the development of pharmaceuticals due to its unique structural properties and potential biological activity. It contributes to the creation of enantiomerically pure compounds, which are essential in the production of effective and safe medications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Azabicyclo[3.1.0] hexane-1-carboxylic acid, 3-(phenylMethyl)-, ethyl ester is employed as a reagent, particularly for the production of drugs and other bioactive compounds. Its cyclopropane structure and proline derivative nature make it a valuable component in the synthesis of complex organic molecules with specific biological functions.
Used in Research and Development:
3-Azabicyclo[3.1.0] hexane-1-carboxylic acid, 3-(phenylMethyl)-, ethyl ester is also utilized in research and development for the exploration of new chemical reactions and the discovery of novel bioactive compounds. Its unique properties allow scientists to investigate its potential applications in various chemical and biological processes, further expanding its use in the scientific community.

Upstream product

• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 623-47-2 propynoic acid ethyl ester 
• 1774-47-6 trimethylsulfoxonium iodide 
• 128259-46-1 ethyl 1-benzyl-2,5-dihydro-1H-pyrrole-3-carboxylate 
• 64-17-5 ethanol 

Downstream Products

• 204991-14-0 tert-butyl N-{3-azabicyclo[3.1.0]hexan-1-yl}carbamate 
• 1204820-62-1 3-tert-butyl 1-ethyl 3-azabicyclo[3.1.0]hexane-1,3-dicarboxylate 

Relevant academic research and scientific papers

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Synthesis of azabicyclo[n.1.0]alkane-derived bifunctional building blocks via the Corey–Chaykovsky cyclopropanation

An efficient approach towards the synthesis of monoprotected azabicyclo[5.1.0]octane-derived conformationally restricted γ-amino acids and diamines is reported. Optimization of the conditions for the key Corey–Chaykovsky reaction allowed the construction

ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS

Disclosed is a series of analogues of 4H-pyrazolo[1,5-α]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine, receptors and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans. The compositions comprising a muscarinic agonist or a pharma.ceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

This invention generally relates to derivatives of substituted azabicyclo hexanes of formula I. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urin